Related Experiment Video
Updated: Jul 4, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
Metabolomic signature reveals dysregulated lipoprotein profile in m.3243A>G carriers: a case-control study
Simone Rask Nielsen1,2, Hien Thi Thu Nguyen3,4, Malene Pontoppidan Stoico3,4
1Department of Clinical Genetics, Aalborg University Hospital, Aalborg, Denmark. s.rask@rn.dk.
Introduction:
The pathogenic mitochondrial gene variant m.3243A>G disrupts oxidative phosphorylation and is associated with insulin resistance, both of which may be linked to unfavorable lipid metabolism. However, the metabolic alterations in m.3243A>G carriers, including what differentiates those with and without diabetes, remain incompletely understood.
Objectives:
To investigate metabolomic profiles in fasting serum and urine samples from m.3243A>G carriers compared to healthy controls.
Methods:
Metabolomic profiling of serum and urine samples using nuclear magnetic resonance-based metabolomics in m.3243A>G carriers (n = 28) was compared to healthy controls matched for age and sex. Additionally, profiles from m.3243A>G carriers with diabetes (n = 16) were compared with carriers without diabetes (n = 12) to identify potential metabolites associated with the presence of diabetes.
Results:
Twenty-five metabolites in serum and 16 in urine were identified as metabolites separating m.3243A>G carriers from healthy controls. The m.3243A>G carriers presented with increased triglycerides across lipoprotein particles and altered very-low-density lipoprotein concentrations and composition. In addition, there were alterations in metabolites from a number of metabolic pathways, including glycolysis, the tricarboxylic acid cycle, glutathione, one-carbon, and nucleotide metabolism. A three metabolite-urine signature (uracil, hypoxanthine, and 1-methylnicotinamide) demonstrated discriminating potential between m.3243A>G carriers and controls in exploratory machine learning analyses (area under the curve values 0.94-0.99 and cross-validation prediction of 0.81-0.93). Among m.3243A>G carriers, branched-chain amino acids were higher in individuals with diabetes compared with carriers without diabetes.
Conclusion:
Dysregulated lipoprotein metabolism represents a significant metabolic fingerprint of m.3243A>G carriers. Furthermore, higher levels of branched-chain amino acids may be associated with the presence of diabetes.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
